(VIANEWS) – Harmony Biosciences Holdings (HRMY), Horizon Therapeutics (HZNP), AtriCure (ATRC) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Harmony Biosciences Holdings (HRMY)

61.4% sales growth and 9.47% return on equity

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders.

Harmony Biosciences Holdings’s sales growth this year is expected to be 91.3% and 53.2% for next year.

Year-on-year quarterly revenue growth grew by 77%, now sitting on 270.52M for the twelve trailing months.

Volume

Today’s last reported volume for Harmony Biosciences Holdings is 486923 which is 41.17% above its average volume of 344915.

Harmony Biosciences Holdings’s sales growth for the next quarter is 61.4%. The company’s growth estimates for the ongoing quarter and the next is 40% and 161.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.47%.

Volatility

Harmony Biosciences Holdings’s last day, last week, and last month’s current intraday variation average was 3.48%, 2.60%, and 2.30%, respectively.

Harmony Biosciences Holdings’s highest amplitude of average volatility was 10.68% (day), 5.80% (last week), and 5.29% (last month), respectively.

Harmony Biosciences Holdings’s Stock Yearly Top and Bottom Value

Harmony Biosciences Holdings’s stock is valued at $40.24 at 06:22 EST, way under its 52-week high of $45.89 and way above its 52-week low of $25.09.

Harmony Biosciences Holdings’s Moving Average

Harmony Biosciences Holdings’s value is higher than its 50-day moving average of $38.55 and way above its 200-day moving average of $35.72.

2. Horizon Therapeutics (HZNP)

27.5% sales growth and 16.1% return on equity

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.

Horizon Therapeutics’s sales growth this year is anticipated to be 41.2% and 23.5% for next year.

Year-on-year quarterly revenue growth grew by 79.9%, now sitting on 2.56B for the twelve trailing months.

Volume

Today’s last reported volume for Horizon Therapeutics is 1295830 which is 21.31% below its average volume of 1646760.

Horizon Therapeutics’s sales growth for the next quarter is 27.5%. The company’s growth estimates for the present quarter and the next is a negative 11.5% and 10.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.1%.

Volatility

Horizon Therapeutics’s last day, last week, and last month’s current intraday variation average was 2.48%, 1.30%, and 1.54%, respectively.

Horizon Therapeutics’s highest amplitude of average volatility was 2.11% (day), 2.46% (last week), and 2.95% (last month), respectively.

Horizon Therapeutics’s Stock Yearly Top and Bottom Value

Horizon Therapeutics’s stock is valued at $103.26 at 06:22 EST, way below its 52-week high of $120.54 and way higher than its 52-week low of $66.41.

Horizon Therapeutics’s Moving Average

Horizon Therapeutics’s worth is below its 50-day moving average of $109.80 and above its 200-day moving average of $100.05.

3. AtriCure (ATRC)

12.6% sales growth and 11.2% return on equity

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally.

AtriCure’s sales growth this year is anticipated to be 17.2% and 16.6% for next year.

Year-on-year quarterly revenue growth grew by 26.8%, now sitting on 274.33M for the twelve trailing months.

Volume

Today’s last reported volume for AtriCure is 15549 which is 94.19% below its average volume of 267733.

AtriCure’s sales growth for the next quarter is 12.6%. The company’s growth estimates for the current quarter and the next is 15.8% and 22.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.2%.

Volatility

AtriCure’s last day, last week, and last month’s current intraday variation average was 3.95%, 2.93%, and 2.92%, respectively.

AtriCure’s highest amplitude of average volatility was 7.28% (day), 5.65% (last week), and 5.96% (last month), respectively.

AtriCure’s Stock Yearly Top and Bottom Value

AtriCure’s stock is valued at $59.61 at 06:22 EST, way below its 52-week high of $89.18 and above its 52-week low of $56.84.

AtriCure’s Moving Average

AtriCure’s worth is under its 50-day moving average of $65.17 and way below its 200-day moving average of $72.61.

4. NMI Holdings (NMIH)

12.4% sales growth and 15.5% return on equity

NMI Holdings, Inc., through its subsidiaries, provides private mortgage guaranty insurance services in the United States.

NMI Holdings’s sales growth this year is expected to be 12.4% and 13.7% for next year.

Year-on-year quarterly revenue growth grew by 15.1%, now sitting on 469.9M for the twelve trailing months.

Volume

Today’s last reported volume for NMI Holdings is 513138 which is 32.25% below its average volume of 757476.

NMI Holdings’s sales growth for the next quarter is 12.4%. The company’s growth estimates for the ongoing quarter and the next is 20.3% and 19.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.5%.

Volatility

NMI Holdings’s last day, last week, and last month’s current intraday variation average was 5.47%, 2.67%, and 2.46%, respectively.

NMI Holdings’s highest amplitude of average volatility was 6.06% (day), 3.57% (last week), and 3.96% (last month), respectively.

NMI Holdings’s Stock Yearly Top and Bottom Value

NMI Holdings’s stock is valued at $21.94 at 06:22 EST, way below its 52-week high of $27.25 and way higher than its 52-week low of $19.43.

NMI Holdings’s Moving Average

NMI Holdings’s value is below its 50-day moving average of $23.82 and below its 200-day moving average of $22.88.

5. Benchmark Electronics (BHE)

12.3% sales growth and 3.18% return on equity

Benchmark Electronics, Inc., together with its subsidiaries, provides product design, engineering services, technology solutions, and advanced manufacturing services in the Americas, Asia, and Europe.

Benchmark Electronics’s sales growth this year is anticipated to be 7.3% and 5.9% for next year.

Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 2.14B for the twelve trailing months.

Volume

Today’s last reported volume for Benchmark Electronics is 11874 which is 93.52% below its average volume of 183286.

Benchmark Electronics’s sales growth for the next quarter is 12.3%. The company’s growth estimates for the current quarter and the next is 20.6% and 47.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.18%.

Volatility

Benchmark Electronics’s last day, last week, and last month’s current intraday variation average was 0.23%, 0.83%, and 1.26%, respectively.

Benchmark Electronics’s highest amplitude of average volatility was 2.14% (day), 2.30% (last week), and 2.56% (last month), respectively.

Benchmark Electronics’s Stock Yearly Top and Bottom Value

Benchmark Electronics’s stock is valued at $25.78 at 06:22 EST, way below its 52-week high of $32.56 and way above its 52-week low of $22.25.

Benchmark Electronics’s Moving Average

Benchmark Electronics’s value is higher than its 50-day moving average of $25.56 and under its 200-day moving average of $26.44.

LEAVE A REPLY

Please enter your comment!
Please enter your name here